COVER-MS Status Report as of May 3, 2021

Participant count: 930

Age

- <=29: 23
- 30-39: 112
- 40-49: 199
- 50-59: 268
- 60-69: 236
- >=70: 87

Sex

- Female: 16%
- Male: 84%

MS Type

- RRMS: 622
- SPMS: 170
- PPMS: 77
- CIS/RIS: 16

Race

- White: 93%
- Black/African-American: 2%
- Native American: <1%
- No Answer: 1%

Ethnicity

- Middle Eastern: <1%
- Asian: <1%
- Native Hawaiian: <1%
- Multi-Racial: 2%

Vaccine Type

- Pfizer: 346
- Moderna: 220
- J&J: 26
- AstraZeneca: 13
- Sinovac: 1
- Don’t Know: 1

What are we learning about experiences with the COVID-19 vaccines?

- 607 participants have received an initial dose with 60% experiencing side effects.
- 339 have received a second dose with 71% experiencing side effects.
- The majority of side effects were reported to be mild or moderate, with injection site pain, fatigue and headache being the most common effects.

Further results will be reported as more data comes in.

Participants represent 18 different countries, 48 different US states and the District of Columbia.

We thank our participants for making this study possible. To enroll in COVER-MS, please join the iConquerMS community at www.iConquerMS.org. Email info@iConquerMS.org for more information.